Ross examines how the FDA's 2004 warnings over potential suicide risks for antidepressants in children may have scared some parents away from these drugs, leading to a surge in teen suicides.
That's one conclusion that can be drawn from a new analysis on the benefits and risks of antidepressants for children and adolescents published by the Journal of the American Medical Association. The analysis found that the risks of these medicines are much lowerby a factor of two or morethan the FDA previously thought. It had concluded from a previous study that young people had a 2% risk of having aberrant thoughts if they took antidepressants. The rate is only 0.7%. Further, the study found that these drugs are effective in treating depression and other mental illnesses found in children and teens. The new study, by the way, was undertaken by the National Institutes of Health and the Robert Wood Johnson Foundationnot Big Pharma.
This isn't the what the FDA led us to believe in 2004, when it released an analysis indicating that young people on antidepressants had about a 2% risk, not of suicide, but of "suicidal thoughts." Antipharmaceutical activists and some politicians immediately called for major restrictions on antidepressants, simply ignoring that since the introduction of modern SSRItype medications in the late 1980s, teen suicide rates had steadily fallen. No, the drumbeat from the "no risk allowed" crowd got the attention of the always risk-averse FDA.
The result was a "Black Box" warningthe strongest possible warning short of an outright banslapped onto the antidepressants. Remember, this was provoked by an alleged increase in thoughts, not deeds. There were no actual suicideszeroin the FDA studies, and none in the latest, more extensive analysis.
Guess what happened next? Parents, naturally as frightened by this new warning as they would be by a skullandcrossbones, decided to forego giving these medicines to their children. Many family doctors, spooked by the prospect of lawsuits, suddenly found other, less effective treatment options more appealing. Primarycare physicians are the ones who prescribe most treatments for depression, not psychiatrists. Since this warning label was introduced, usage of SSRI medications declined by more than 14% from 2004 to 2006 among patients under 19 years old. And, no surprise, actual suicides, not hypothetical ones, increased 18% among youngsters during the first year of the Black Box warningsthe first such increase in many years.
When the FDA was quizzed by renowned psychiatristsmany of whom had disparaged the original warningspokespersons for the FDA said, in effect, that the new study wasn't surprising and that they weren't forbidding the drugs, merely asking doctors to warn patients and monitor them.